2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Treatment Considerations, Combination Therapy, Supportive Care, Therapy Sequence, Non-Biological Therapies, Chemotherapy, Adverse Events, Biological Processes, Immune Mechanism, Clinical Practice (Health Services and Quality), Diseases, Myeloid Malignancies, Acute Myeloid Malignancies, Measurable Residual Disease, Research, AML, Clinical Research, Clinical Trials, Health Outcomes Research, Real-World Evidence, Study Population, Human, Adult, Elderly
PAPER

1666 Longer-term outcomes of ascertain-v using all oral therapy (decitabine/cedazuridine + venetoclax) in older/unfit patients (pts) with newly diagnosed (ND) acute myeloid leukemia (AML) according to the PRISM score.

Amer M. Zeidan, MD, Elizabeth A Griffiths, MD2, Gabriel Mannis I, MD3, Michael R. Savona, MD4, Yubing Wan5, Qing Xu6, Harold Keer, MD, PhD7, Courtney DiNardo, MD, MSCE8, Gail J Roboz, MD9
1 Yale School of Medicine - Yale Cancer Center, New Haven, Connecticut, United States
2 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
3 Stanford University School of Medicine, Stanford, California, United States
4 Vanderbilt University School of Medicine, Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
5 Taiho Oncology, Inc., Princeton, New Jersey, United States
6 Taiho Oncology, Inc., Princeton, New Jersey, United States
7 Taiho Oncology, Inc., Princeton, New Jersey, United States
8 The University of Texas MD Anderson Cancer Center - Leukemia Center, Houston, Texas, United States
9 Weill Medical College of Cornell University, New York, New York, United States

Introduction: ASCERTAIN-V was a phase 1/2  study with a pivotal Phase 2B cohort of the all oral combination of venetoclax (V) with decitabine/cedazuridine (DEC-C) in ND AML pts not suitable for intensive chemotherapy. The trial resulted in US, European Union (EU) member states, and European Economic Area (EEA) countries approval of this regimen, with complete response (CR) rate 47% and median overall survival (mOS) over 15 months(mo) (Roboz GJ and Zeidan A et al, NEJM 2026;394:2107-2116).  The PRISM Score is a recently developed tool to assess risk for AML patients receiving hypomethylating agents (HMA) + V, taking into account 17 clinical and genomic variables (Lachowiez, et al. JCO 2026) and builds on the previously described 4-gene panel (Dohner H et al, Blood 144:2788-2792, 2024).  We here report longer-term outcomes and describe clinical outcomes in patients from ASCERTAIN-V based on the PRISM score.

Methods: Of the subjects enrolled and treated on ASCERTAIN-V, Phase 2B (n=101), 96 had all required data to allow risk classification by both PRISM and 4-gene panel scores. Pts were grouped by PRISM scores: high risk (HR), moderate risk (MR), and low risk (LR)  categories (worse to better prognosis) using the PRISM online calculator.  Pts were also classified by the 4-gene panel into adverse (ADV), intermediate (INT), and favorable (FAV) risk groups. Clinical outcomes included OS, CR rate, complete response with partial hematologic recovery (CRh) rate, and duration of response (DOR).

Results: After PRISM scoring, in total, 37 (38.5%),  44 (45.8%), and 15 (15.6%) pts were classified as HR, MR, and LR by PRISM, and had median follow up of 28.3, 31.5, and 30.3 mo, respectively.  By the 4-gene panel, 17 (17.7%), 29 (30.2%), and 50 (52.1%) pts were classified into ADV, INT, and FAV risk. Reclassification from 4-gene to PRISM risk groups resulted in reassignment for a majority of patients (57.3%). Fifty-two subjects moved to a worse category (FAV to MR/HR or INT to HR) while only 3 moved to better risk categories (INT to LR, ADV to MR). Notably of 50 subjects classified as FAV with the 4-gene panel, only 14 remained LR, while 30 and 6 moved to MR and HR, respectively, suggesting the population had a worse prognosis than predicted by the 4-gene score. 

After reclassification, demographics were generally similar for the three groups  (HR/MR/LR) with median age  78.0/78.0/76.0 (across all groups 38.5% were ≥80 years); majority of subjects male except in LR group with 61.5%/67.4%/35.7%;  were ECOG 0-1: 76.9/81.4/85.8. The majority of pts were treated in North America vs. EU in all groups. Baseline hemoglobin, abolute neutrophil counts, and platelets were generally similar, though median bone marrow blast percentages were more variable with median percentages of 36.0, 48.5, and 60.5 for HR/MR/LR and the vast majority in all groups had ≥ 20% BM blast%.  

Response rates were higher and of longer duration in PRISM LR and MR groups.  CR/CR+CRh rates were 21.6%/29.7%, 61.4 %/68.2%, and 53.3 %/66.7%, in HR, MR, and LR groups, respectively. Median DOR in HR individuals were 10.7/9.5 months for CR/CR+CRh, respectively, but had not yet been reached for MR and LR individuals. At 30-month landmark analyses, the % of subjects remaining in CR/CR+CRh were 61.5%/55.8% and 72.9%/70%, for MR and LR patients, respectively.

Similarly, OS results differed across PRISM  risk classification with mOS of 6.0 mo (95% CI 3.3,8.9), 19.4 mo (95% CI: 12.6,NE), and 31.5 mo (95% CI: 8.0, NE), for HR, MR, and LR, respectively. Percent survival at 12 and 24-mo for the groups were 30.7 % (95% CI:16.7, 45.8), 67.7% (95% CI:51.6, 79.5), and  80.0 (95% CI: 50.0, 93.1), and  9.6% (95% CI: 2.5,22.3), 42.6 (95% CI: 27.3, 57.0), and 60.0 (95% CI: 31.8,79.7) for HR, MR, and LR, groups, respectively.  These results appear to compare favorably to those of the original PRISM population where  mOS were 6.6, 14.6, and 25.3 mo. for HR, MR, and LR groups respectively and 12/24-mo percent survival were 26%/10%, 57%/34%, and 69%/52%, respectively for HR, MR, and LR, respectively.

Conclusions: In long term follow-up, pts treated in ASCERTAIN V trial with total oral regimen of DEC-C+VEN continued to have durable responses and survival rates, especially those in the PRISM MR and LR groups. These data provide important benchmarks to counsel patients about expected outcomes based on their individualized risk profiles. 

Amer M. Zeidan, MD: AbbVie, Akesobio, Agios, Amgen, Astellas, BioCryst, BioThera, BeiOne, Boehringer Ingelheim, Celgene/BMS, Chiesi/Cornerstone, Daiichi-Sankyo, Dr.Reddy’s, Epizyme, Faron, Fibrogen, GSK, Glycomimetics, Genentech, Gilead, Geron, Innocare, Janssen, Jasper, Karyopharm, Kyowa Kirin, Keros, Kura, Novartis, Notable, Oncoverity, Orum, Otsuka, Pfizer, Puretech/Gallop Technology, Regeneron, Rigel, Seattle Genetics, Shattuck Labs, Schrodinger, Sumitomo, Syros, Syndax, Systimmune, Sillajen, Servier, Takeda, Treadwell, Taiho, Vincerx, and Zentalis - Consultancy (Includes expert testimony); AbbVie, Akesobio, Agios, Amgen, Astellas, BioCryst, BioThera, BeiOne, Boehringer Ingelheim, Celgene/BMS, Chiesi/Cornerstone, Daiichi-Sankyo, Dr.Reddy’s, Epizyme, Faron, Fibrogen, GSK, Glycomimetics, Genentech, Gilead, Geron, Innocare, Janssen, Jasper, Karyopharm, Kyowa Kirin, Keros, Kura, Novartis, Notable, Oncoverity, Orum, Otsuka, Pfizer, Puretech/Gallop Technology, Regeneron, Rigel, Seattle Genetics, Shattuck Labs, Schrodinger, Sumitomo, Syros, Syndax, Systimmune, Sillajen, Servier, Takeda, Treadwell, Taiho, Vincerx, and Zentalis - Consultancy (Includes expert testimony)